Rasagiline — Membership Pricing

Other medications in Neurological

• Riluzole
• Rimegepant
• Risdiplam
• Rivastigmine
• Rizatriptan
• Ropinirole
• Rufinamide
• Selegiline

What Rasagiline is approved for (FDA label)

Rasagiline tablets are indicated for the treatment of Parkinson's disease (PD). Rasagiline tablets, a monoamine oxidase (MAO)-B inhibitor (MAOI), is indicated for the treatment of Parkinson’s disease ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: August 26, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Rasagiline (FDA label)

Rasagiline tablets 1 mg: White to off white, uncoated round, flat, beveled tablets debossed with “RAS” on one side and “1” on other side containing, as the active ingredient, rasagiline mesylate equivalent to 1 mg of rasagiline base. Rasagiline tablets 1 mg tablets ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 9bf059f4-4da8-48fe-aacb-c50717d36606. SPL document ID: 59f2b413-b6fd-a9ec-e063-6294a90a13e1. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Rasagiline (FDA label)

The following adverse reactions are described in more detail in the Warnings and Precautions section of the label: Hypertension [ see Warnings and Precautions ( 5.1 ) ] Serotonin Syndrome [ see Warnings and Precautions ( 5.2 ) ] Falling Asleep During Activities of Daily Living and Somnolence [ see Warnings and Precautions ( 5.3 ) ] Hypotension / Orthostatic Hypotension [ see Warnings and Precautions ( 5.6) ] Dyskinesia [ see Warnings and Precautions ( 5.7 ) ] Hallucinations / Psychotic-Like Behavior [ see Warnings and Precautions ( 5.8 ) ] Impulse Control /Compulsive Behaviors [ see Warnings and Precautions ( 5.9 ) ] Withdrawal-Emergent Hyperpyrexia and Confusion [ see Warnings and Precautions ( 5.10 ) ] Most common adverse reactions (incidence 3% or greater than placebo): Rasagiline monotherapy: flu syndrome, arthralgia, depression, dyspepsia ( 6.1 ) Rasagiline used as adjunct without levodopa: peripheral edema, fall, arthralgia, cough, and insomnia ( 6.1 ) Rasagiline used as adjunct to levodopa: dyskinesia, accidental injury, weight loss, postural hypotension, vomiting, anorexia, arthralgia, abdominal pain, nausea, constipation, dry mouth, rash, abnormal dreams, fall, and tenosynovitis ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Northstar Rx LLC at Toll free number: 1-800-206-7821 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the incidence of adverse reactions in the clinical trials of another drug and may not reflect the rates of adverse reactions observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 9bf059f4-4da8-48fe-aacb-c50717d36606. SPL document ID: 59f2b413-b6fd-a9ec-e063-6294a90a13e1. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Rasagiline (FDA label)

Rasagiline is contraindicated for use with meperidine, tramadol, methadone, propoxyphene and MAO inhibitors (MAOIs), including other selective MAO-B inhibitors, because of risk of serotonin syndrome [see Warnings and Precautions ( 5.2 )] . At least 14 days should elapse between discontinuation of rasagiline and initiation of treatment with these medications. Rasagiline is contraindicated for use with St. John’s wort and with cyclobenzaprine. Rasagiline is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. Concomitant use of meperidine, tramadol, methadone, propoxyphene dextromethorphan, St. John’s wort, cyclobenzaprine, or another (selective or non-selective) MAO inhibitor

Source: FDA prescribing information (DailyMed). Set ID: 9bf059f4-4da8-48fe-aacb-c50717d36606. SPL document ID: 59f2b413-b6fd-a9ec-e063-6294a90a13e1. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Rasagiline (FDA label)

May cause hypertension (including severe hypertensive syndromes) at recommended doses ( 5.1 ) May cause serotonin syndrome when used with antidepressants ( 5.2 ) May cause falling asleep during activities of daily living, daytime drowsiness, and somnolence ( 5.3 ) May cause hypotension, especially orthostatic ( 5.6 ) May cause or exacerbate dyskinesia. Decreasing the levodopa dose may lessen or eliminate this side effect ( 5.7 ) May cause hallucinations and psychotic-like behavior ( 5.8 ) May cause impulse control/compulsive behaviors ( 5.9 ) May cause withdrawal-emergent hyperpyrexia and confusion ( 5.10 ) 5.1 Hypertension Exacerbation of hypertension may occur during treatment with rasagiline. Medication adjustment may be necessary if elevation of blood pressure is sustained. Monitor patients for new onset hypertension or hypertension that is not adequately controlled after starting rasagiline.

Source: FDA prescribing information (DailyMed). Set ID: 9bf059f4-4da8-48fe-aacb-c50717d36606. SPL document ID: 59f2b413-b6fd-a9ec-e063-6294a90a13e1. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Rasagiline (FDA label)

Meperidine: Risk of serotonin syndrome ( 4 , 7.1 ) Dextromethorphan: Risk of psychosis or bizarre behavior ( 4 , 7.2 ) MAO inhibitors: Risk of non-selective MAO inhibition and hypertensive crisis ( 4 , 7.3 ) 7.1 Meperidine Serious, sometimes fatal reactions have been precipitated with concomitant use of meperidine (e.g., Demerol and other trade names) and MAO inhibitors including selective MAO-B inhibitors [see Contraindications ( 4 )]. 7.2 Dextromethorphan The concomitant use of rasagiline and dextromethorphan was not allowed in clinical studies. The combination of MAO inhibitors and dextromethorphan has been reported to cause brief episodes of psychosis or bizarre behavior.

Source: FDA prescribing information (DailyMed). Set ID: 9bf059f4-4da8-48fe-aacb-c50717d36606. SPL document ID: 59f2b413-b6fd-a9ec-e063-6294a90a13e1. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.